April 2, 2014 Critical Path Institute Receives Grant to Accelerate Development of Tuberculosis Treatments
October 10, 2013 CDISC SHARE and CFAST Integrally Linked: A Major Topic at the 2013 CDISC International Interchange
Innovative Data and Analytics Platform to Accelerate Drug Development for Rare Diseases Launched by C-Path and NORD through an FDA grant, the goal of the new platform is to accelerate the development of cures by addres
C-Path’s PSTC Releases Points to Consider Outlining Recommendations for Analytical Validation of Assays Used in Qualifying Biomarkers The document serves as a guide to the analysis of biomarkers in drug development TUCSON, Ariz., June 11, 2019 — The Critical Pat
C-Path Receives Qualification for the Asthma Daytime Symptom Diary (ADSD) and the Asthma Nighttime Symptom Diary (ANSD) TUCSON, Ariz., April 9, 2019 — Critical Path Institute’s (C-Path) Patient-Reported Outcome (PRO) Consortium announces U.S.
Critical Path Institute Rebrands One of Its First Consortia to Highlight Focus on Alzheimer’s Disease Critical Path for Alzheimer’s Disease (CPAD) consortium’s refined, refocused mission centers on accelerating therapy developme
C-Path Appoints Dr. Amanda Klein as Executive Director for CPLD and CPA-1 Consortia TUCSON, Ariz., April 17, 2024 — Critical Path Institute (C-Path) today announced the appointment of Amanda Klein, Pharm.D., as E
C-Path Forms Data Collaboration with International Niemann-Pick Disease Registry (INPDR) to Propel Niemann-Pick Disease Research Forward TUCSON, Ariz. April 17, 2024 — Critical Path Institute (C-Path), a leader in advancing rare disease research, today announced a